AC‑262 (AC‑262536, Accadrine)

Detailed overview

AC-262 (AC-262536) is a non-steroidal selective androgen receptor modulator developed by ACADIA Pharmaceuticals and characterised in the Piu 2008 paper. That work is the compound's only substantial pharmacological description, and it is preclinical: cell-based and rat models. It reports that AC-262 binds the androgen receptor as a partial agonist, exerts anabolic effects in muscle and stimulates the prostate less than testosterone does. That is precisely the selectivity profile expected of the SARM class. The story ends where most such compounds' stories end: development never reached human clinical trials. No controlled experiment in humans has ever been performed with AC-262, so there are no human efficacy, dosing or safety data. What has appeared in the literature since is of a different kind: Cutler 2021 studied its metabolism in horses for doping control, and Stacchini 2021 developed a urinary detection method. The pattern is familiar: the compound is studied today so it can be detected, not so it can be used. The Solomon 2019 SARM review provides the frame: across the class, HPTA suppression, lipid deterioration and drug-induced liver injury are documented. These are plausible for AC-262 too, but it bears emphasis that this is inference from structural kinship rather than measurement.